ImpediMed Limited
(ASX:IPD) has announced it will partner with Vanderbilt University for a series of clinical trials involving patients and clinicians.
The trial will test the hardware and software behind ImpediMed’s latest bioimpedance spectroscopy technology platform.
Researchers will observe the technology in use in both clinical and at-home settings.
Research will be undertaken at the Vanderbilt University School of Nursing, which is part of the independent and privately supported Vanderbilt University.
ImpediMed Limited reported a net loss of $11.22 million at 31 December 2015.
